Overseas Studies May Not Be Worth Oversight Costs, Consultants Suggest
This article was originally published in The Pink Sheet Daily
Overseas clinical trials could save companies money, but consultants on a regulatory panel at the Biotechnology Industry Organization's Mid-America VentureForum in Cleveland suggested such studies might not be worth the oversight costs
You may also be interested in...
Assuming a study will need to be large could lead to cost-savings if stopped early, while starting with a small design could result in problems if expansion is needed.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.